Indeed, treatment with a selective glutaminase inhibitor CB-83954 strongly suppressed cell viability and proliferation (Fig. 4e–g, Supplementary Fig. 5a, b), reduced OXPHOS (Fig. 4h, i), and induced apoptosis (Supplementary Fig. 5c) in SMARCA4/2-deficient ovarian and lung cancer cell lines, but not in proficient controls. This evidence concerns the gene SMARCA4 and lung carcinoma.